Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Мигрень

Список литературы

  1. Амелин А.В., Игнатов Ю.Д., Скоромец А.А., Соколов А.Ю. Мигрень (патогенез, клиника, лечение). М.: МЕДпресс, 2011; 265 с.
  2. Осипова В.В, Табеева Г.Р. Первичные головные боли: диагностика, клиника, терапия: Практическое руководство. М.: ООО «Издательство «Медицинское информационное агентство», 2014; 336 с.
  3. Табеева Г.Р., Яхно Н.Н. Мигрень. М.: ГЭОТАР-Медиа, 2011; 622 с.
  4. Сергеев А.В., Табеева Г.Р., Азимова Ю.Э. Центральная нейрональная гипервозбудимость - предиспозиция к мигрени. Российский журнал боли. 2010; 2(27): 3-11.
  5. Rasmussen B.K., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general population — a prevalence study. J Clin Epidemiol. 1991; 44:1147–1157.
  6. Ayzenberg I., Katsarava Z., Sborowski A. et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012; 32(5): 373–381.
  7. Лебедева Е.Р., Кобзева Н.Р., Гилев Д.В., Олесен Ес. Анализ качества диагностики и лечения первичных головных болей в различных социальных группах Уральского региона. Неврология, нейропсихиатрия, психосоматика. 2015; 1: 19-26.
  8. The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018; 38(1): 1-211.
  9. Осипова В.В. Мигрень и головная боль напряжения. В: Клинические рекомендации. Неврология и нейрохирургия. Под ред. Е.И. Гусева, А.Н. Коновалова. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015; 424 с.
  10. Li D., Christensen A.F., Olesen J. Field-testing of the ICHD-3 beta/proposed ICD-11 diagnostic criteria for migraine with aura. Cephalalgia. 2015; 35(9): 748-756.
  11. Lebedeva E.R., Gurary N.M., Gilev D.V., Olesen J. Prospective testing of ICHD-3 beta diagnostic criteria for migraine with aura and migraine with typical aura in patients with transient ischemic attacks. Cephalalgia. 2018; 38(3): 561-567.
  12. Lebedeva E.R., Gurary N.M., Gilev D.V. et al. Explicit diagnostic criteria for transient ischemic attacks to differentiate it from migraine with aura. Cephalalgia. 2018; 38(8): 1463-1470.
  13. Екушева Е.В., Карпова М.И., Осипова В.В. Гормональные контрацептивы и риск ишемического инсульта у женщин с мигренью: новый международный консенсус. Неврология, нейропсихиатрия и психосоматика. 2019; 11(3): 11-15.
  14. Артеменко А.Р., Куренков А.Л., Беломестова К.В. Классификация, диагностика и лечение хронической мигрени: обзор новых данных. Журн. неврологии и психиатрии им. Корсакова. 2013; 11: 91-96.
  15. Осипова В.В., Филатова Е.Г., Артеменко А.Р. с соавт. Диагностика и лечение мигрени: рекомендации российских экспертов. Журнал неврологии и психиатрии им. Корсакова 2017; 2: 28-42.
  16. Westergaard M.L., Hansen E.H., Glümer C. et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014; 34(6): 409-425.
  17. Zeeberg P., Olesen J., Jensen R. Medication overuse headache and chronic migraine in a specialized headache centre: field-testing proposed new appendix criteria. Cephalalgia. 2009; 29(2): 214-220.
  18. Steiner T.J., MacGregor E.A., Davies P.T.G. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type, cluster and medication overuse headache. British Association for the Study of Headache, 3rd edn. 2007.
  19. Tepper S.J., Dahlöf C.G., Dowson A. et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004; 44(9): 856-864.
  20. Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. J. Headache Pain. 2012; 13: S1–S29.
  21. Lipton R.B., Serrano D., Buse D.C. et al. Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia. 2016; 36(3): 203-215.
  22. Jiang H., Deng Y., Zhang Y. et al. Field testing of the ICHD-3β and expert opinion criteria for chronic migraine. J. Headache Pain. 2016; 17(1): 85.
  23. Lampl C., Buzath A., Yazdi K., Sandor P.S. Ergot and triptan overuse in Austria—an evaluation of clinical data and cost. Cephalalgia. 2002; 22: 807–811.
  24. Mitsikostas D., Ashina M., Craven A. et al. EHF committee. European headache federation consensus on technical investigation for primary headache disorders. J. Headache Pain. 2015; 17: 5.
  25. American Academy of Neurology. The utility of neuroimaging in the evaluation of headache in patients with normal neurological examinations. Neurology. 1994; 44: 1353–1354.
  26. Kruit M.C., van Buchem M.A., Launer L.J. et al. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: the population-based MRI CAMERA study. Cephalalgia. 2010; 30(2): 129-36.
  27. Екушева Е.В. Многоликая женская мигрень. М.: МЕДпресс-информ, 2019; 96 с.
  28. Mett A., Tfelt-Hansen P. Acute migraine therapy: recent evidence from randomized comparative trials. Curr. Opin. Neurol. 2008; 21(3): 331-337.
  29. Orr S.L., Aube´ M., Becker W.J. et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015; 35: 271.
  30. Kirthi V., Derry S., Moore R. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013; 4: CD008041.
  31. Lampl C., Voelker M., Diener H.C. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J. Neurol. 2007; 254(6): 705-712.
  32. Suthisisang C., Poolsup N., Kittikulsuth W. et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Annals of Pharmacotherapy. 2007; 41(11): 1782-1791.
  33. Rabbie R., Derry S., Moore R.A. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013; 4: CD008039.
  34. Suthisisang C.C., Poolsup N., Suksomboon N. et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache. 2010; 50(5): 808-818.
  35. Law S., Derry S., Moore R.A. Naproxen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013; 10: CD009455.
  36. Derry S., Rabbie R., Moore R.A. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013; 4: CD008783.
  37. Derry S., Moore R.A. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst. Rev. 2013; 4: CD008040.
  38. Diener H.C., Montagna P., Gacs G. et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006; 26: 537-547.
  39. Colman I., Brown M.D., Innes G.D. et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004; 329(7479): 1369-1373.
  40. Turkcuer I., Serinken M., Eken C. et al. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: A randomised clinical trial. Emerg. Med. J. 2014; 31: 182-185.
  41. Shrestha M., Singh R., Moreden J., Hayes J.E. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura. A prospective, randomized, double-blind trial. Arch. Intern. Med. 1996; 156: 1725-1728.
  42. Duarte C., Dunaway F., Turner L. et al. Ketorolac versus meperidine and hydroxyzine in the treatment of acute migraine headache: A randomized, prospective, double-blind trial. Ann. Emerg. Med. 1992; 21: 1116-1121.
  43. Friedman B.W., Mulvey L., Esses D. et al. Metoclopramide for acute migraine: a dose finding randomized clinical trial. Ann. Emerg Med. 2011; 57(5): 475-482.
  44. Friedman B.W., Garber L., Yoon A. et al. Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014; 82: 976-983.
  45. Kellstein D.E., Lipton R.B., Geetha R. et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia. 2000; 20: 233-243.
  46. Cameron C., Kelly S., Hsieh S.C. et al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015; 55(Suppl 4): 221-235.
  47. Ferrari M.D., Goadsby P.J., Roon K.I., Lipton R.B. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
  48. Lipton R.B., Bigal M.E., Goadsby P.J. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication. A review. Cephalalgia. 2004; 24: 321-332.
  49. Pascual J., Mateos V., Roig C. et al. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007; 47: 1152-1168.
  50. Thorlund K., Mills E.J., Wu P. et al. Comparative efficacy of triptans for the abortive treatment of migraine: A multiple treatment comparison meta-analysis. Cephalalgia. 2014; 34: 258-267.
  51. Derry C.J., Derry S., Moore R.A. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst. Rev. 2012: CD008615.
  52. Smith LA., Oldman A.D., McQuay H.J., Moore R.A. Eletriptan for acute migraine. Cochrane Database Syst. Rev. 2001: CD003224.
  53. Cady R.K., Sheftell F., Lipton R.B. et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin. Ther. 2000; 22(9): 1035-1048.
  54. Olesen J., Diener H.C., Schoenen J., Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. 2004; 11: 671-677.
  55. Филатова Е.Г., Амелин А.В., Табеева Г.Р. с соавт. Ready - первое российское мультицентровое исследование эффективности препарата релпакс (элетриптан) при лечении мигрени. Лечение нервных болезней. 2006; 2: 19-22.
  56. Bigal M.E., Bordini C.A., Speciali J.G. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J. Emerg. Med. 2002; 23(2):141-148.
  57. Cameron J.D., Lane P.L., Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad. Emerg. Med. 1995; 2(7): 597-602.
  58. Gungor F., Akyol K.C., Kesapli M. et al. Intravenous dexketoprofen vs placebo for migraine attack in the emergency department: A randomized, placebo-controlled trial. Cephalalgia. 2016; 36: 179-184.
  59. Bigal M.E., Bordini C.A., Tepper S.J. et al. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura: A randomized, doubleblind, placebo-controlled study. Cephalalgia. 2002; 22: 345-353.
  60. Corbo J., Esses D., Bijur P.E. et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann. Emerg. Med. 2001; 38: 621-627.
  61. Cete Y., Dora B., Ertan C. et al. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005; 25: 199-204.
  62. Leniger T., Pageler L., Stude P., Diener H.C., Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache. 2005; 45: 42-46.
  63. Tanen D.A., Miller S., French T., Riffenburgh R.H. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: A prospective, randomized, double-blind trial. Ann. Emerg. Med. 2003; 41: 847-853.
  64. Woldeamanuel Y.W., Rapoport A.M., Cowan R.P. The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia. 2015; 35(11): 996–1024.
  65. Friedman B.W., Greenwald P., Bania T.C. et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007; 69: 2038–2044.
  66. Colman I., Friedman B.W., Brown M.D. et al. Parenteral dexamethasone for acute severe migraine headache: Meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008; 336: 1359-1361.
  67. Neill A., Brannigan D. Towards evidence-based emergency medicine: Best BETs from the Manchester Royal Infirmary. BET 2: Dexamethasone for reduction of migraine recurrence. Emerg. Med. J. 2013; 30: 165-166.
  68. Huang Y., Cai X., Song X. et al. Steroids for preventing recurrence of acute severe migraine headaches: A metaanalysis. Eur. J. Neurol. 2013; 20: 1184–1190.
  69. Wang S.J., Silberstein S.D., Young W.B. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997; 37: 377-382.
  70. Silberstein S.D., Young W.B., Mendizabal J.E. et al. Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial. Neurology. 2003; 60(2): 315-321.
  71. Honkaniemi J., Liimatainen S., Rainesalo S. et al. Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. Headache. 2006; 46(5): 781-787.
  72. Gaffigan M.E., Bruner D.I., Wason C. et al. A randomized controlled trial of intravenous haloperidol vs. intravenous metoclopramide for acute migraine therapy in the emergency department. J. Emerg. Med. 2015; 49: 326.
  73. Balbin JEB., Nerenberg R., Baratloo A. Intravenous fluids for migraine: a post hoc analysis of clinical trial data. Am. J. Emerg. Med. 2016; 34: 713–716.
  74. Dekker F., Neven A.K., Andriesse B. et al. Prophylactic treatment of migraine by GPs: a qualitative study. Br. J. Gen. Pract. 2012; 62(597): 268-274.
  75. Jackson J.L., Cogbill E., Santana-Davila R. et al. Comparative effectiveness meta-analysis of drugs for the pophylaxis of migraine headache. PLoS One. 2015; 10(7): e0130733.
  76. He A., Song D., Zhang L., Li C. Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis. J. Headache Pain. 2017; 18(1): 26.
  77. Silberstein S., Tfelt-Hansen P., Dodick D.W. et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008; 28: 484-495.
  78. Silva-Néto R.P., Almeida K.J., Bernardino S.N. Analysis of the duration of migraine prophylaxis. J. Neurol. Sci. 2014; 337(1-2): 38-41.
  79. Holroyd K.A., Penzien D.B., Cordingley G.E. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache. 1991; 31(5): 333-40.
  80. Kangasniemi P., Hedman C. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia. 1984; 4: 91-96.
  81. Chronicle E.P., Mulleners W.M. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev. 2016; 5: CD003226.
  82. Linde M., Mulleners W.M., Chronicle E.P. et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst. Rev. 2013; 6: CD010611.
  83. Bussone G., Diener H.C., Pfeil J. et al. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int. J. ClinPract. 2005; 59: 961-968.
  84. Silberstein S.D., Lipton R.B., Dodick D.W. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007; 47: 170-180.
  85. Herd C.P., Tomlinson C.L., Rick C. et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst. Rev. 2018; 6: CD011616
  86. Dodick D.W., Ashina M., Brandes J.L. et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38:1026–1037.
  87. Dodick DW et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial. JAMA. 2018; 319(19): 1999-2008.
  88. Tepper S., Ashina M., Reuter U. et al. Safety and efficacy of erenumab forpreventive treatment of chronic migraine: a randomised, double-blind,placebo-controlled phase 2 trial. Lancet Neurol. 2017; 16: 425–434.
  89. Bigal M. et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015; 14: 1081–90.
  90. Jackson J.L., Shimeall W., Sessums L., et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010; 341: c5222.
  91. Xu X.M., Yang C., Liu Y. et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur. J. Neurol. 2017; 24(8): 1022-1031.
  92. Bulut S., Berilgen M.S., Baran A. et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin. Neurol. Neurosurg. 2004; 107: 44-48.
  93. Ozyalcin S.N., Talu G.K., Kiziltan E. et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005; 45: 144-152.
  94. Tronvik E., Stovner L.J., Helde G. et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-69.
  95. Stovner L.J., Linde M., Gravdahl G.B. et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014; 34(7): 523-32.
  96. Kindelan-Calvo P., Gil-Martínez A., Paris-Alemany A. et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med. 2014; 15(9): 1619-1636.
  97. Anheyer D., Leach M.J., Klose P. et al. Mindfulness-based stress reduction for treating chronic headache: A systematic review and meta-analysis. Cephalalgia. 2018; 1: 333102418781795.
  98. Diener H.C., Bussone G., Van Oene J.C. et al. TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27(7): 814-23.
  99. Cady R.K., Schreiber C.P., Porter J.A. et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011; 51(1): 21-32.
  100. Negro A., Curto M., Lionetto L., Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015; 17: 1.
  101. Fritsche G, Frettloh J, Huppe M. et al. Prevention of medication overuse in patients with migraine. Pain. 2010; 151: 404–413.
  102. Limmroth V., Biondi D., Pfeil J. et al. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache. 2007; 47: 13–21.
  103. Rossi P., Di Lorenzo C., Faroni J. et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006; 26: 1097–1105.
  104. de Goffau M.J., Klaver A.R., Willemsen M.G. et al. The effectiveness of treatments forpatients with medication overuse headache; A systematic review and meta-analysis. J Pain. 2017; 18: 615–627.
  105. Hagen K., Albretsen C., Vilming S.T. et al. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia. 2018; 38: 225-236.
  106. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007; 27: 814–823.
  107. Silberstein S.D., Lipton R.B., Dodick D.W. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007; 47: 170–180
  108. Silberstein S.D., Blumenfeld A.M., Cady R.K. et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013; 331: 48–56.
  109. Sandrini G., Perrotta A., Tassorelli C. et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011; 12: 427–433.
  110. Negro A., Curto M., Lionetto L., Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA. 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015; 17: 1.
  111. Silberstein S.D., Ashina S., Katsarava Z. et al. The impact of fremanezumab on medication overuse in patients with chronic migraine. Headache. 2018; 58: 76–77.
  112. Pazdera L., Ning X., Campos V.R. et al. Efficacy of fremanezumab in patients with migraine and documented inadequate response to 3 or 4 migraine preventive medication classes and medication overuse in the international, multicenter, randomized placebo-controlled FOCUS study. Poster, 14th European Headache Federation Congress, 2020.
  113. Tepper S.J., Diener H.C., Ashina M. et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019; 92: e2309–e2320.
  114. Tassorelli C., Jensen R., Allena M. et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014; 34: 645–655.
  115. Trucco M., Meineri P., Ruiz L., Gionco M. Medication overuse headache: withdrawal and prophylactic therapeutic regimen. Headache. 2010; 50: 989–997.
  116. Zeeberg P., Olesen J., Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia. 2005; 25: 1159–1167.
  117. Zeeberg P., Olesen J., Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006; 26: 1192–1198.
  118. Munksgaard S.B., Bendtsen L., Jensen R.H. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: acomparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012; 32: 834–844.
  119. Carlsen L.N., Munksgaard S.B., Jensen R.H. et al. Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia. 2018; 38: 225–236.
  120. Pageler L., Katsarava Z., Diener H.C. et al. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008; 28: 152-156.
  121. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic induced daily headache. Cephalalgia. 2000; 20:107–13.
  122. Cevoli S., Giannini G., Favoni V. et al. Treatment of withdrawal headache in patients with medication overuse headache: a pilot study. J Headache Pain. 2017; 18(1): 56.
  123. Paolucci M., Altamura C., Brunelli N. et al. Methylprednisolone plus diazepam i.v. as bridge therapy for medication overuse headache. Neurol Sci. 2017; 38(11): 2025-2029.
  124. Trucco M., Meineri P., Ruiz L. "Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee" (Neurological Hospital Interregional Group for the Study of Headache). Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain. 2005; 6(4): 334-337.
  125. Tassorelli C., Jensen R., Allena M. et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014; 34: 645–655.
  126. Fiesseler F.W., Shih R., Szucs P. et al. Steroids for migraine headaches: a randomized double-blind, twoarmed, placebo-controlled trial. J Emerg Med. 2011; 40: 463–468.
  127. Taghdiri F., Togha M., Razeghi J.S., Paknejad S.M. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015; 55(1): 128-35.
  128. Rossi P., Di Lorenzo C., Faroni J. et al. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized trial in transformed migraine patients with low medical needs. Cephalalgia. 2006; 26(9): 1097-105.
  129. Rabe K., Pageler L., Gaul C. et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: A randomized, double-blind, placebo-controlled study. Cephalalgia. 2013; 33: 202-207.
  130. Huang Y., Cai X., Song X. et al. Steroids for preventing recurrence of acute severe migraine headaches: a meta-analysis. Eur. J. Neurol. 2013; 20(8): 1184-1190.
  131. Sandrini G., Perrotta A., Tassorelli C. et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: A multicenter, double-blind, randomized, placebo-controlled, parallel group study. J. Headache Pain. 2011; 12: 427–433.
  132. Silberstein S.D., Blumenfeld A.M., Cady R.K. еt al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J. Neurol Sci. 2013; 331: 48-56.
  133. Luedtke K., Allers A., Schulte L.H et al. Efficacy of interventions used by physiotherapists for patients with headache and migraine. Systematic review and meta-analysis. Cephalalgia. 2016; 36(5): 474-492.
  134. Millstine D., Chen C.Y., Bauer B. Complementary and integrative medicine in the management of headache. BMJ. 2017; 357: j1805.
  135. Giannitrapani K., Holliday J., Miake-Lye I. еt al. Synthesizing the strength of the evidence of complementary and integrative health therapies for pain. Pain Med. 2019; pii: pnz068.
  136. Lee H.J., Lee J.H., Cho E.Y. еt al. Efficacy of psychological treatment for headache disorder: a systematic review and meta-analysis. J. Headache Pain. 2019; 20(1): 17.
  137. Anheyer D., Leach M.J., Klose P. еt al. Mindfulness-based stress reduction for treating chronic headache: A systematic review and meta-analysis. Cephalalgia. 2019; 39(4): 544-555.
  138. Probyn K., Bowers H., Mistry D. еt al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. BMJ Open. 2017; 7(8): e016670.
  139. Harris P., Loveman E., Clegg A. et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults. Br. J. Pain. 2015; 9(4): 213-224.
  140. Kindelan-Calvo P., Gil-Martínez A., Paris-Alemany A. et al. Effectiveness of therapeutic patient education for adults with migraine. A systematic review and meta-analysis of randomized controlled trials. Pain Med. 2014; 15(9): 1619-1636.
  141. Golovacheva V., Parfenov V., Tabeeva G. et al. Multidisciplinary integrated headache treatment program: results and identification of factors that influence treatment response. Eur J of Neurol. 2016; 23(Suppl.1): 536.
  142. Nestoriuc Y., Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. 2007; 128(1-2): 111-127.
  143. Nestoriuc Y., Martin A., Rief W., Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl. Psychophysiol. Biofeedback. 2008; 33: 125-140.
  144. Xu J., Zhang F.Q., Pei J., Ji J. Acupuncture for migraine without aura: a systematic review and meta-analysis. J Integr Med. 2018; 16(5):312-321.
  145. Yin Jiang, Peng Bai, Hao Chen. et al. The Effect of Acupuncture on the Quality of Life in Patients With Migraine: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018; 9: 1190.
  146. Feng-Jiao Shen, Jia Xu, Yi-Jun Zhan. et al. Acupuncture for migraine: A systematic review and meta-analysis. World Journal of Acupuncture – Moxibustion. 2019; 29(1): 7-14.
  147. Falsiroli M.L., Geri T., Gianola S. et al. Effectiveness of trigger point manual treatment on the frequency, intensity, and duration of attacks in primary headaches: a systematic review and meta-analysis of randomized controlled trials. Front. Neurol. 2018; 9: 254.
  148. Lemmens J., De Pauw J., Van Soom T. et al. The effect of aerobic exercise on the number of migraine days, duration and pain intensity in migraine: a systematic literature review and meta-analysis. J. Headache Pain. 2019; 20(1): 16.
  149. Krøll L.S., Hammarlund C.S., Linde M., et al. The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial. Cephalalgia. 2018; 38(12): 1805-1816.
  150. Allen S.M., Mookadam F., Cha S.S. Greater occipital nerve block for acute treatment of migraine headache: a large retrospective cohort study. J Am Board Fam Med. 2018; 1(2): 211-218.
  151. Cuadrado M.L., Aledo-Serrano Á., Navarro P. et al. Short-term effects of greater occipital nerve blocks in chronic migraine: a double-blind, randomised, placebo-controlled clinical trial. Cephalalgia. 2017; 37: 864–872.
  152. Misra U.K, Kalita J., Bhoi S.K. High-rate repetitive transcranial magnetic stimulation in migraine prophylaxis: a randomized, placebo-controlled study. J. Neurol. 2013; 260(11): 2793-801.
  153. Lan L., Zhanq X., Li X. et al. The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails. J. Headache Pain. 2017; 18(1): 86.
  154. Conforto A.B., Amaro E. Jr., Gonçalves A.L. et al. Randomized, proof-of-principle clinical trial of active transcranial magnetic stimulation in chronic migraine. Randomized controlled trial. Cephalalgia. 2014; 34(6): 464-472.
  155. Stilling J.M., Monchi O., Amoozegar F., Debert C.T. Transcranial magnetic and direct currents (TMS/tDCS) for the treatment of headache: a systematic review. Headache. 2019; 59(3): 339-357.
  156. Schoenen J., Vandersmissen B., Jeangette S. et al. Migraine prevention with a supraorbital transcutaneous stimulator. A-randomized-controlled-trial. Neurology. 2013; 80: 697–704.
  157. Chou D., Yugrakh M., Winegarne D. et al. Acute migraine therapy with external trigeminal neurostimulation ACME: A randomized controlled trial. Cephalalgia. 2019; 39(1): 3–14.
  158. Miller S., Sinclair A.J., Davies B. et al. Neurostimulation in the treatment of primary headaches. Pract Neurol. 2016; 16(5): 362–375.
  159. Исагулян Э.Д., Екушева Е.В., Артеменко А.Р. c соавт. Нейромодуляция в лечении первичных форм головной боли: механизмы эффективности, обзор методов и показания к применению. Российский журнал боли. 2018; 3(57): 5–15.
  160. Осипова В.В., Екушева Е.В., Исагулян Э.Д. с соавт. Инвазивная нейромодуляция в лечении рефрактерных форм мигрени и кластерной головной боли: критерии отбора пациентов и обзор эффективности. Российский журнал боли. 2019; 17(1): 9-16.
  161. Cadalso R.T., Daugherty J., Holmes C. et al. Efficacy of Electrical Stimulation of the Occipital Nerve in Intractable Primary Headache Disorders: A Systematic Review with Meta-Analyses. J Oral Facial Pain Headache. 2018; 32(1): 40-52.
  162. Yang Y., Song M., Fan Y., Ma K. Occipital Nerve Stimulation for Migraine: A Systematic Review. Pain Pract. 2016; 16(4): 509-517.
  163. Deer T., Levy R., Diaz R.L. et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32(16): 1165-79.
  164. Tepper S.J., Rezai A., Narouze S. et al. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009; 49(7): 983–989.
  165. Ho K.W.D., Przkora R., Kumar S. Sphenopalatine ganglion: block, radiofrequency ablation and neurostimulation - a systematic review. The Journal of Headache and Pain. 2017; 18(1): 118.
  166. Luedtke K., Allers A., Schulte L.H., May A. Efficacy of interventions used by physiotherapists for patients with headache and migraine. Systematic review and meta-analysis. Cephalalgia. 2016; 36(5): 474-492.
  167. Martelletti P., Jensen R.H., Antal A. et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. The Journal of Headache and Pain. 2013; 14(1): 86.

Порядок обновления клинических рекомендаций по мигрени предусматривает их систематическую актуализацию – не реже чем один раз в три года, а также при появлении новых данных с позиции доказательной медицины по вопросам диагностики, лечения, профилактики и реабилитации мигрени, наличии обоснованных дополнений/замечаний к ранее утверждённым КР, но не чаще 1 раза в 6 месяцев.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*